<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889252</url>
  </required_header>
  <id_info>
    <org_study_id>CR-4539</org_study_id>
    <nct_id>NCT00889252</nct_id>
  </id_info>
  <brief_title>Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers</brief_title>
  <official_title>A Single-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vistakon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vistakon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lid and Lid Margin Erythema, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lid and Lid Margin Swelling, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Chemosis, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Edema, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Erosion, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Endothelial, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Pathology, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flare in Anterior Chamber, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cells in Anterior Chamber, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining - Nasal, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining - Temporal, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining - Inferior, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining - Superior, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining - Central, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure - Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dilated Ophthalmoscopy - Fundus, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dilated Ophthalmoscopy - Vitreous, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity Assessment</measure>
    <time_frame>at the 12 week visit</time_frame>
    <description>Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>K-Lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lens</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>contact lens with ketotifen</intervention_name>
    <description>K-Lens (generic name not established) and Ketotifen combination drug-device product</description>
    <arm_group_label>K-Lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>contact lens</intervention_name>
    <description>Placebo contact lens</description>
    <arm_group_label>Placebo Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy normal, soft contact lens wearing volunteers

          -  normal ocular health

          -  contact lens correction from +6.00 to -12.00D in each eye and astigmatism of -1.00D or
             less in each eye

        Exclusion Criteria:

          -  active ocular infection

          -  history of ocular surgery

          -  use of topical ophthalmic preparations (including rewetting drops)

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Pall, OD, MS, FAAO</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Vision Care, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <results_first_submitted>October 4, 2010</results_first_submitted>
  <results_first_submitted_qc>October 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2010</results_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>K-Lens</title>
          <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo Lens</title>
          <description>contact lens without drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>K-Lens</title>
          <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo Lens</title>
          <description>contact lens without drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="12.48"/>
                    <measurement group_id="B2" value="29.3" spread="10.77"/>
                    <measurement group_id="B3" value="31.5" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lid and Lid Margin Erythema, Change From Baseline</title>
        <description>Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Lid and Lid Margin Erythema, Change From Baseline</title>
          <description>Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lid and Lid Margin Swelling, Change From Baseline</title>
        <description>Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Lid and Lid Margin Swelling, Change From Baseline</title>
          <description>Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness, Change From Baseline</title>
        <description>Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness, Change From Baseline</title>
          <description>Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.67"/>
                    <measurement group_id="O2" value="-0.1" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Chemosis, Change From Baseline</title>
        <description>Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Chemosis, Change From Baseline</title>
          <description>Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Edema, Change From Baseline</title>
        <description>Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Edema, Change From Baseline</title>
          <description>Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Erosion, Change From Baseline</title>
        <description>Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Erosion, Change From Baseline</title>
          <description>Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Endothelial, Change From Baseline</title>
        <description>Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Endothelial, Change From Baseline</title>
          <description>Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Pathology, Change From Baseline</title>
        <description>Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Pathology, Change From Baseline</title>
          <description>Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.23"/>
                    <measurement group_id="O2" value="0" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flare in Anterior Chamber, Change From Baseline</title>
        <description>Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Flare in Anterior Chamber, Change From Baseline</title>
          <description>Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cells in Anterior Chamber, Change From Baseline</title>
        <description>Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Cells in Anterior Chamber, Change From Baseline</title>
          <description>Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining - Nasal, Change From Baseline</title>
        <description>Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining - Nasal, Change From Baseline</title>
          <description>Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.27"/>
                    <measurement group_id="O2" value="0" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining - Temporal, Change From Baseline</title>
        <description>Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining - Temporal, Change From Baseline</title>
          <description>Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.20"/>
                    <measurement group_id="O2" value="0" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining - Inferior, Change From Baseline</title>
        <description>Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining - Inferior, Change From Baseline</title>
          <description>Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.51"/>
                    <measurement group_id="O2" value="0.0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining - Superior, Change From Baseline</title>
        <description>Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining - Superior, Change From Baseline</title>
          <description>Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.13"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining - Central, Change From Baseline</title>
        <description>Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining - Central, Change From Baseline</title>
          <description>Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.19"/>
                    <measurement group_id="O2" value="0" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure - Change From Baseline</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure - Change From Baseline</title>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.45"/>
                    <measurement group_id="O2" value="0.6" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dilated Ophthalmoscopy - Fundus, Change From Baseline</title>
        <description>Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Dilated Ophthalmoscopy - Fundus, Change From Baseline</title>
          <description>Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dilated Ophthalmoscopy - Vitreous, Change From Baseline</title>
        <description>Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Dilated Ophthalmoscopy - Vitreous, Change From Baseline</title>
          <description>Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe.</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity Assessment</title>
        <description>Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit.</description>
        <time_frame>at the 12 week visit</time_frame>
        <population>Subjects that completed the study per protocol were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>K-Lens</title>
            <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lens</title>
            <description>contact lens without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity Assessment</title>
          <description>Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit.</description>
          <population>Subjects that completed the study per protocol were included in this analysis.</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>K-Lens</title>
          <description>Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo Lens</title>
          <description>contact lens without drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Gallstones, unrelated to test article.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign adenoma</sub_title>
                <description>Benign tumor on an ovary, unrelated to test article.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator agrees not to publish or publicly present the results of the study without the prior written approval of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Pall OD MS FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-1290</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

